CELU represents Celularity Inc., a biotechnology company centered on cellular and regenerative medicine. It stands out for its work on off-the-shelf cell therapies sourced from postpartum human placentas, a supply that tends to be plentiful, ethically sourced, and less controversial than certain alternatives. I follow developments here because the combination of this cell therapy focus with a commercial biomaterials operation aims to narrow the typical distance between early research and some level of revenue.
Celularity was established in 2016 and maintains its headquarters in Florham Park, New Jersey. The core idea centers on the placenta as a renewable source of cells and biomaterials suitable for scaled therapeutic use. The firm reached public markets via a SPAC merger with GX Acquisition Corp., resulting in the CELU ticker. Leadership comes from founder, Chairman, and CEO Dr. Robert J. Hariri, whose background spans cell therapy and regenerative medicine. With a compact team, the organization balances focused R&D with commercial activities.
Operations break down across Cell Therapy, Degenerative Disease, and BioBanking segments. Most current revenue stems from commercial products and services, consistent with the clinical-stage profile. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Main components include allogeneic cell therapy candidates such as placental-derived T cells and NK cells for cancer and related conditions, plus commercial biomaterials sold under names like Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex for surgical and wound applications. The LifebankUSA brand handles BioBanking of umbilical cord blood and placental tissue. The IMPACT platform supports integrated sourcing, processing, and manufacturing. Partnerships include a licensing deal on CAR-T products with Sorrento Therapeutics and a research collaboration with Regeneron Pharmaceuticals. Earlier programs explored PDA-001 and PDA-002 for inflammatory, autoimmune, and degenerative indications including Crohn’s disease, multiple sclerosis, and diabetic peripheral neuropathy.
Celularity competes in the broader cell therapy and regenerative medicine space against larger biotechs and pharma firms as well as other clinical-stage players. Its edge lies in the placental platform, which it views as scalable and consistent. The mix of a commercial biomaterials line alongside the therapeutic pipeline sets it apart from many early-stage peers and may supply revenue while candidates move through trials.
Attention centers on exposure to longevity-oriented regenerative medicine, particularly treatments for aging-related and degenerative conditions. The off-the-shelf, placental-derived method could deliver manufacturing and cost benefits over personalized autologous therapies if it succeeds. The biomaterials and BioBanking operations provide a somewhat steadier profile than pure pre-revenue biotechs. Collaboration agreements with established pharma companies also offer a form of external validation for the platform.
Clinical-stage biotech investing involves notable uncertainties. Candidates must still prove safety and efficacy in trials and obtain regulatory clearance, steps that are time-consuming, costly, and unpredictable. Operational and financial pressures exist as well. The firm has posted net losses and has encountered Nasdaq compliance matters tied to filing delays. Biomaterials face competition and oversight, while BioBanking hinges on consumer demand and reimbursement. Revenue remains limited relative to research goals, and the modest market capitalization can amplify share-price swings and liquidity constraints.
When evaluating names like Celularity against thousands of other stocks, I turn to Tickeron’s AI-powered platforms to cross-check technical indicators, fundamentals, and sector patterns. These tools help surface comparable ideas quickly and support a more structured review process without replacing individual judgment.
Celularity holds a distinct position where cell therapy meets regenerative medicine and longevity themes. Its placental platform, paired with commercial biomaterials and BioBanking activities, creates a broader profile than many pure-play biotech peers. Even so, it remains an early-stage company facing meaningful clinical and financial uncertainties. CELU therefore embodies a higher-risk profile tied to the longer-term progress of cell-based approaches.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
CELU saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 85 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
CELU moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CELU crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CELU entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELU advanced for three days, in 213 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
CELU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.197) is normal, around the industry mean (3.596). P/E Ratio (-0.228) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1.244) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. CELU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a blank check company, which focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization
Industry Biotechnology